NCT05134662View on ClinicalTrials.gov

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

February 3, 2023

Study Completion Date

March 9, 2023

Conditions
Type 2 Diabetes
Interventions
DRUG

ALT-801

Injected subcutaneously (SC)

OTHER

Placebo

Injected subcutaneously (SC)

Trial Locations (7)

33900

Altimmune CTM, Fort Myers

34230

Altimmune CTM, Sarasota

37922

Altimmune CTM, Knoxville

60305

Altimmune CTM, River Forest

64101

Altimmune CTM, Kansas City

77375

Altimmune CTM, Tomball

78201

Altimmune CTM, San Antonio

Sponsors

Lead Sponsor

Altimmune, Inc.
All Listed Sponsors
lead

Altimmune, Inc.

INDUSTRY

NCT05134662 - ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter | Biotech Hunter